Clinical Challenges in HCV infection- Mark Sulkowski, MD

HEP DART 2017

Eliminating HCV Transmission by Enhancing Care and Treatment Among HCV/HIV Co-infected Individuals in Australia (not available)- Joseph Doyle, MD

HEP DART 2017

Management of HCV in Decompensated liver disease- Michael Manns

HEP DART 2017

DAA Controversies: Do they Cause HBV Reactivation and/or HCC?- Jordan Feld, MD, MPH

HEP DART 2017

Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination- Tarik Asselah

HEP DART 2017

When are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR? (not available)- Paul Pockros

HEP DART 2017

Long term follow-up after treatment with Ombitasvir/Paritaprevir/ritonavir ±Dasabuvir ±Ribavirin in the AMBER – real world experience study- Dr. R. Flisiak

HEP DART 2017

Update on Merck’s HCV Program- Mike Robertson

HEP DART 2017

A Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization- Dr. N. Mani

HEP DART 2017

NASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes- Arun Sanyal

HEP DART 2017

Predicting Susceptibility and Resistance for Hepatitis B Virus Capsid Assembly Effectors- Dr. B. Cox

HEP DART 2017

Evolving Role of Real-World Evidence in NASH and HCC: From Bench to Poolside (not available)- Michael Fried

HEP DART 2017

Sustained SVR 2 years after HCV treatment with simeprevir, daclatasvir and sofosbuvir in patients with portal hypertension or decompensated liver disease (not available)- Dr. E. Lawitz

HEP DART 2017

High Efficacy and Safety of the combination HCV Regimen Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non-severe fibrosis HCV GT1b-Infected Patients: Interim Results of the STREAGER study- Dr. A. Abergel

HEP DART 2017

The Re-vival of Bile Acid Based Therapeutics for Children and Adults- Saul Karpen

HEP DART 2017

Update on Prophylactic HCV Vaccine Development- Andrea Cox, MD

HEP DART 2017

Hepatitis B virus splice variants are associated with and predictive of Liver cancer- Dr. P. Revill

HEP DART 2017

Seroclearance of HBsAg in Chronic Hepatitis B Virus Patients on Lamivudine, Tenofovir or Entecavir Therapy: A 10 Year Experience- Dr. S. Ono

HEP DART 2017

Lessons learned towards a Vaccine and Functional Cure for HIV (not available)- Mario Stevenson

HEP DART 2017

Liver Directed Acetyl-CoA Carboxylase Inhibitor GS-0976 For NASH (not available)- Adrian Ray

HEP DART 2017

The Effectiveness of Treatment for Chronic Hepatitis C (and Hepatitis B) in Pediatric Populations- Manal El-Sayed, MD, PhD

HEP DART 2017

Aramchol for NASH and beyond: From scientific rationale to clinical development- Carol Brosgart

HEP DART 2017

WHO status report: Global response to the strategic framework- Yvan Hutin, MD, PhD

International Viral Hepatitis Elimination Meeting (IVHEM) 2017

Real-life experiences - Egypt- Imam Waked, MD

International Viral Hepatitis Elimination Meeting (IVHEM) 2017